Document Detail


Does PPI therapy predispose to Clostridium difficile infection?
MedLine Citation:
PMID:  19713988     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Clostridium difficile infection (CDI) has emerged as a problem of epidemic proportions. Previous exposure to broad-spectrum antibiotics remains the most important predisposing factor for the disease. However, PPIs are increasingly being overprescribed and recent research has, therefore, focused on the association between PPI therapy and CDI. While the data remain observational, increasing evidence exists for at least a modest association between PPI use and CDI.
Authors:
Chaitanya Pant; Phillip Madonia; Anil Minocha
Related Documents :
21326348 - The polymicrobial nature of airway infections in cystic fibrosis: cangene gold medal le...
778288 - Superficial mycoses.
21470468 - Human metapneumovirus infection in wild mountain gorillas, rwanda.
24942028 - Autoimmune neutropenia of infancy with recurrent urinary tract infections: a case report.
22556678 - Antimicrobial activity of essential oil of leonotis nepetaefolia.
16822638 - Review of in vitro activity of sertaconazole nitrate in the treatment of superficial fu...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Nature reviews. Gastroenterology & hepatology     Volume:  6     ISSN:  1759-5053     ISO Abbreviation:  Nat Rev Gastroenterol Hepatol     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-08-28     Completed Date:  2009-11-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101500079     Medline TA:  Nat Rev Gastroenterol Hepatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  555-7     Citation Subset:  IM    
Affiliation:
Louisiana State University Health Sciences Center and Overton Brooks VA Medical Center, Shreveport, LA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Bacterial Agents / adverse effects
Clostridium difficile*
Enterocolitis, Pseudomembranous / epidemiology,  etiology*
Esophagitis / drug therapy,  metabolism
Gastric Acid / metabolism
Humans
Peptic Ulcer / drug therapy,  metabolism
Proton Pump Inhibitors / adverse effects*,  pharmacology,  therapeutic use
Risk Factors
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Proton Pump Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Insights into the future of gastric acid suppression.
Next Document:  Design, synthesis and antibacterial activity of a novel alkylide: 3-O-(3-aryl-propenyl)clarithromyci...